Generic Drug Regulation in the US Under the Hatch-Waxman Act: A Balance Between Competition and Innovation or Confusion and Intrigue?

Author： Milne C-P.   Cairns C.  

Publisher： Adis International

ISSN： 1175-9046

Source： Pharmaceutical Development and Regulation, Vol.1, Iss.1, 2003-01, pp. : 11-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Hatch-Waxman Act: Encouraging Innovation and Generic Drug Competition

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 18, 2010-12 ,pp. : 1950-1959

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 18, 2010-12 ,pp. : 1960-1970

Bentham Science Publishers

Access to resources Recommend Favorite

Judicial developments in the US Hatch-Waxman infringement safe harbor

By Swirnoff Alexander H   Becker Daniel M  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 4, 2010-04 ,pp. : 451-458

Informa Healthcare

Access to resources Recommend Favorite

Hatch-Waxman in the Federal Courts: From 1994–2004

By Ludwig S.   Kosinski Kristin Behrendt   Harris Jonathan  

Drug Development and Industrial Pharmacy, Vol. 31, Iss. 2, 2005-02 ,pp. : 215-222

Informa Healthcare

Access to resources Recommend Favorite

How did Abbott avoid generic fenofibrate competition?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 652, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite